Skip to main content

Table 2 CYP3A4-392A>G and ABCB1 3435C>T genotype frequencies and risk of recurrency during the 28-day follow-up (IC95%)

From: The drug transporter ABCB1 c.3435C>T SNP influences artemether–lumefantrine treatment outcome

Gene/SNP

Genotype frequencies (IC 95%)

Recurrence-free group

Recurrence group

CYP3A4*1B

AA

AG

GG

AA

AG

GG

8/71 (0.113; 0.053–0.215)

37/71 (0.521; 0.400–0.640)

26/71 (0.366; 0.258–0.490)

3/28 (0.107; 0.028–0.294)

10/28 (0.357; 0.193–0.559)

15/28 (0.536; 0.342–0.720)

ABCB1 3435C>T

CC

CT

TT

CC

CT

TT

 

60/72* (0.833; 0.723–0.907)

10/72* (0.077; 0.072–0.245)

2/72* (0.028; 0.005–0.106)

17/29* (0.586; 0.391–0.760)

6/29* (0.207; 0.087–0.403)

6/29* (0.207; 0.087–0.403)

CYP3A5*3

AA

AG

GG

AA

AG

GG

 

46/59 (0.780; 0.653–0.877)

11/59 (0.186; 0.097–0.309)

2/59 (0.034; 0.004–0.117)

17/25 (0.680; 0.465–0.851)

6/25 (0.240; 0.094–0.451)

2/25 (0.080; 0.010–0.260)

  1. * Significant (p < 0.01)
  2. Recurrence-free group without positive PCR during the follow-up days
  3. Recurrence group with positive PCR during the follow-up days